You are here
PHOENIX PHARMACOLOGICS, INC.
UEI: N/A
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Preclinical Development of PEG-TNF
Amount: $808,828.00DESCRIPTION (provided by applicant): Unformulated human tumor necrosis factor( (huTNF() has anti-tumor activity in mice, but there is little difference between the effective and lethal doses. Systemi ...
SBIRPhase II2004Department of Health and Human Services National Institutes of Health -
Preclinical Development of PEG-TNF
Amount: $0.00DESCRIPTION (provided by applicant): Unformulated human tumor necrosis factor( (huTNF() has anti-tumor activity in mice, but there is little difference between the effective and lethal doses. Systemi ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health -
PRECLINICAL DEVELOPMENT OF URICASE-PEG 20
Amount: $100,000.00Hyperuricemia (elevated serum uric acid) results in gouty arthritis and chronic renal disease. Severe hyperuricemia can occur following cancer chemotherapy (tumor lysis syndrome) and organ transplanta ...
SBIRPhase I2002Department of Health and Human Services National Institutes of Health -
Arginine deiminase as an Anti-Cancer Therapy
Amount: $0.00DESCRIPTION: The distinctive arginine requirement of hepatocellular carcinomas and malignant melanomas provides the basis for a new potential chemotherapy. Just as acute lymphocytic leuk ...
SBIRPhase I2001Department of Health and Human Services National Institutes of Health -
Arginine deiminase as an Anti-Cancer Therapy
Amount: $383,600.00DESCRIPTION: The distinctive arginine requirement of hepatocellular carcinomas and malignant melanomas provides the basis for a new potential chemotherapy. Just as acute lymphocytic leuk ...
SBIRPhase II2001Department of Health and Human Services National Institutes of Health -
MODIFIED TNF-ALPHA: AN ANTI CANCER THERAPY
Amount: $99,962.00DESCRIPTION (PROVIDED BY APPLICANT): The long-term goal of the proposed research is the development of effective anti-cancer agents, modified human tumor necrosis factor-alphas ( ...
SBIRPhase I2001Department of Health and Human Services National Institutes of Health -
ARGININE DEIMINASE AS AN ANTI-CANCER THERAPY
Amount: $100,492.00Not Available A novel high temperature inductive turbine blade tip clearance sensor is proposed to meet the needs indicated by the Air Force and corroborated by several turbine manufacturers for rese ...
SBIRPhase I1999Department of Health and Human Services
